Between 20-30 million Americans live with a rare disease.
While the complexities for rare disease treatment are numerous, the last few years have shown major strides towards meaningful progress. In honor of Rare Disease Day 2021, join us as we explore hurdles and opportunities for biotech and pharmaceutical companies to make an impact on the rare disease sector.
On Thursday, February 25th
, Robert Groebel, Vice President, Global Medical Strategy at Monocl and Bobby Gleavy, Associate Vice President, Biopharma Division at Definitive Healthcare will sit down to discuss the rare disease market in 2021 through a data-driven lens. Topics will include:
- Which rare disease states will show the most growth in the next 3-5 years?
- How do Medical Affairs professionals identify experts to work with throughout the drug development process?
- What complications do drug developers face when recruiting for clinical trials within such small patient populations?
About the Presenters
Robert Groebel, Vice President, Global Medical Strategy, Monocl
With nearly 25 years in the healthcare arena, and diverse experience in commercial and medical organizations internationally, Robert brings a skill set and perspective that is rare among pharmaceutical professionals. His expertise includes both domestic and international sales and product marketing, and deep experience in medical affairs, strategic operations, administration, and staffing.
In his current role, he guides commercial & medical affairs organizations globally to leverage technology, data, and analytics to enhance engagement, scientific, communications, and account management strategies in today’s increasingly complex healthcare landscape.
Robert Gleavy, Associate Vice President, BioPharma Division, Definitive Healthcare
With over a decade of experience in the healthcare space, Robert has a strong foundation in research and data. His hands-on sales and consulting experience within the biotech and pharmaceutical industries, has helped small and enterprise-level companies successfully penetrate and advance the provider market.